NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Oral cabotegravir (CAB)
Drug: CAB LA
Drug: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)

First Posted Date: 2021-04-01

Last Posted Date: 2024-12-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 55

Registration Number: NCT04824131

Locations: 🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
🇿🇦
Ward 21 CRS, Johannesburg, Gauteng, South Africa
🇿🇼
Spilhaus CRS, Harare, Zimbabwe

Daratumumab and Belatacept for Desensitization

Phase 1

Recruiting

Conditions: Highly Sensitized Prospective Kidney Transplant Recipients

Interventions: Biological: daratumumab
Biological: belatacept
Procedure: Bone marrow aspiration

First Posted Date: 2021-04-01

Last Posted Date: 2024-01-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT04827979

Locations: 🇺🇸
University of California at San Francisco Medical Center, San Francisco, California, United States

A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: Env-C Plasmid DNA
Biological: HIV Env gp145 C.6980 protein
Drug: Rehydragel®
Biological: ALF43
Biological: dmLT
Drug: Placebo (IM)
Drug: Placebo (TCl)

First Posted Date: 2021-04-01

Last Posted Date: 2024-12-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 126

Registration Number: NCT04826094

Locations: 🇰🇪
Kenya Medical Research Institute/Walter Reed Project, Clinical Research Centre, Off Hospital Road, Kericho, Kenya

The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal Microorganisms

Recruiting

Conditions: COVID-19

First Posted Date: 2021-03-24

Last Posted Date: 2024-06-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1500

Registration Number: NCT04813328

Locations: 🇮🇳
National Institute for Research in Tuberculosis - International Centers for Excellence in Research (NIRT-ICER), Chennai, Tamilnadu, India

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

Phase 3

Completed

Conditions: SARS-CoV-2 Infection

Interventions: Biological: Moderna COVID-19 Vaccine

First Posted Date: 2021-03-23

Last Posted Date: 2023-08-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1923

Registration Number: NCT04811664

Locations: 🇺🇸
Charles Drew University, Los Angeles, California, United States
🇺🇸
The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
🇺🇸
Stony Brook University, Stony Brook, New York, United States

and more 48 locations

Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini Study

Active, not recruiting

Conditions: HIV

First Posted Date: 2021-03-16

Last Posted Date: 2024-03-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT04799483

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Systems Biology of Early Atopy

Recruiting

Conditions: Atopic Dermatitis
Food Allergy
Allergic Diseases

First Posted Date: 2021-03-15

Last Posted Date: 2024-04-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2500

Registration Number: NCT04798079

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 9 locations

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

Recruiting

Conditions: Influenza
COVID-19

First Posted Date: 2021-03-12

Last Posted Date: 2024-10-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 150

Registration Number: NCT04794829

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

Phase 1

Completed

Conditions: COVID-19
COVID-19 Immunisation

Interventions: Biological: mRNA-1273
Biological: mRNA-1273.351

First Posted Date: 2021-03-05

Last Posted Date: 2024-03-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 135

Registration Number: NCT04785144

Locations: 🇺🇸
The Hope Clinic of Emory University, Decatur, Georgia, United States
🇺🇸
Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States

and more 1 locations

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: ChAdV68-S-TCE
Biological: SAM-LNP-S-TCE
Biological: ChAdV68-S
Other: Sodium Chloride, 0.9%
Biological: SAM-LNP-S

First Posted Date: 2021-03-01

Last Posted Date: 2024-06-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 81

Registration Number: NCT04776317

Locations: 🇺🇸
The Hope Clinic of Emory University, Decatur, Georgia, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy